IM vs. subcutaneous peptide injections: what the evidence actually says

What did @anaglow01 actually say?

Honestly? It's hard to tell. The transcript for this video is largely incoherent, jumping between cheerleading in New York, airplane travel, and vague references to injections feeling "so great" and "so good." The caption asks "Intramuscular ou subcutânea?" which suggests the video was meant to compare IM and subcutaneous injection routes for peptides. But the actual spoken content doesn't deliver that comparison in any coherent way. What we can extract is a loose claim that injection technique affects how something "feels," and an implication that one method may be easier than the other. That's about it. Any fact-check here has to work from the video's stated premise, because the transcript doesn't provide usable claims.

For the record, the injection route question is a legitimate and genuinely important one in peptide administration. It deserves a real answer, which the video does not appear to provide.

Does the science back this up?

The science on IM versus subcutaneous injection for peptides is real, nuanced, and often misrepresented online. The short version: route of administration affects absorption rate, bioavailability, and onset, but the "better" route depends entirely on the peptide and the clinical goal.

Subcutaneous injection delivers a peptide into the fatty tissue just beneath the skin. Absorption is slower and more gradual, which suits peptides like CJC-1295 or ipamorelin where a sustained release profile is preferred. A 2006 pharmacokinetic study by Vahl et al. in the Journal of Clinical Endocrinology and Metabolism confirmed that subcutaneous GLP-1 analogs show predictable, sustained absorption curves. Intramuscular injection delivers directly into muscle tissue, which has greater vascular density, producing faster absorption and a sharper peak concentration. This matters for peptides where timing relative to training or sleep is a factor.

For peptides like BPC-157, some practitioners prefer subcutaneous near the injury site based on localized delivery theory, though high-quality human pharmacokinetic data for most research peptides remains limited. The honest answer is that the evidence base is thinner than most TikTok content implies.

What did they get wrong (or right)?

Since the transcript is largely unintelligible, it's impossible to credit or correct specific technical claims. What we can say is that framing injection technique as primarily about how something "feels" rather than pharmacokinetics is a common and problematic tendency in peptide content online.

The feel of an injection, meaning comfort, sting, or local reaction, is a real consideration. Subcutaneous injections are generally less painful for self-administration. IM injections in sites like the deltoid or glute carry more discomfort and a small but real risk of hitting a nerve or blood vessel if technique is poor. These are legitimate practical differences.

But comfort is not the same as efficacy. Prioritizing how an injection feels over what the pharmacokinetics actually support is backwards reasoning. If this video was encouraging people to choose a route based on subjective experience rather than the specific peptide's absorption profile and intended effect, that's a gap worth flagging. A study by Richter et al. (2012, Diabetes, Obesity and Metabolism) showed that route-dependent pharmacokinetic differences meaningfully affected outcomes for subcutaneous versus IM insulin, a well-studied analog. Peptides deserve the same rigor, not vibes.

What should you actually know?

If you're looking at peptide therapy and weighing injection routes, here is what the actual literature and clinical practice guidelines support. Subcutaneous is the standard first-line route for most research peptides, including growth hormone secretagogues like ipamorelin and CJC-1295, because it allows for predictable, sustained absorption and is easier for self-administration with lower complication risk.

Intramuscular is faster but not inherently superior. It introduces more variability depending on injection site, muscle mass, and blood flow at the time of injection. For peptides without strong pharmacokinetic data in humans, the argument for IM over subcutaneous is often anecdotal.

Needle gauge, injection depth, rotation of sites, and sterile technique matter as much as route selection. A poorly executed subcutaneous injection can become intramuscular by accident depending on body composition and needle length. None of this should be managed without clinical supervision. Compounded peptides, which are what most people accessing peptide therapy outside of clinical trials are using, are not FDA-approved drugs, and their sterility and concentration depend entirely on the compounding pharmacy's quality controls.

• Always confirm route of administration with a licensed prescriber who knows the specific peptide and your individual health status.
• Subcutaneous is generally safer and easier for self-administration.
• IM provides faster peak concentrations but is not automatically more effective.